Immunomedics IMMU autoimmune and other serious diseases, today reported initial
clinical experience with a combination of epratuzumab, the Company's humanized
anti-CD22 antibody, labeled with the radioisotope, yttrium-90 (^90Y), and
veltuzumab, the Company's humanized anti-CD20 antibody, in patients with
relapsed aggressive non-Hodgkin lymphoma (NHL).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in